This Market Spotlight report covers the Endometriosis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways Datamonitor Healthcare estimates that in 2016, there were 186.9 million prevalent cases of endometriosis in women aged 15–49 years worldwide, and forecasts that number to increase to 196.6 million prevalent cases by 2025. Endometriosis affects an estimated 1 in 10 women in the reproductive age group of 15–49 years. The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II. Therapies in mid- and late-stage development for endometriosis focus on targets such as the gonadotropin-releasing hormone (GnRH) receptor, progesterone receptor, and luteinizing hormone receptor. Among these therapies, Elagolix, a first-in-class GnRH receptor antagonist, is closest to market. All pipeline drugs in mid- and late-stage development for endometriosis are administered via the oral route. Approved drugs in the endometriosis space target the GnRH receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available. The main high impact upcoming event in the endometriosis space is topline Phase III trial results for Relugolix. There were 11 licensing and asset acquisition activities involving endometriosis drugs during 2012–17. The largest deal was in 2017, when AstraZeneca obtained commercialization rights to Zoladex in the US and Canada from TerSera Therapeutics for $320m. A composition patent for Lupron is set to expire in 2019, opening the door to generic entry. Lupron’s sales ranked highest among drugs approved in the endometriosis space during 2012–16. Elagolix, which is estimated to be launched in 2018, is expected to achieve blockbuster sales by 2021. The distribution of clinical trials across Phase I–IV indicates that the majority of drugs are in the early and mid-phases of development, with 76% of trials in Phase I–II, and only 24% in Phase III–IV. The US has a substantial lead in the number of endometriosis clinical trials globally, yet forecasted prevalent cases of endometriosis are lower in North America as compared to Europe and Asia. Germany leads the major EU markets, while Japan has the top spot in Asia, where prevalent cases of endometriosis are highest. Clinical trial activity in the endometriosis space is dominated by completed trials, with only 10% of trials currently ongoing. Bayer, Takeda, AbbVie, and Neurocrine Biosciences have the highest number of completed clinical trials for endometriosis.
Our reports have been used by over 10K customers, including:
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
Bacterial Endocarditis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Bacterial Endocarditis Global Clinical Trials Review, H2, 2018" provides an overview of Bacterial Endocarditis clinical trials scenario.This report provides top line data relating to the clinical...
158 pages •
By Roots Analysis Private Ltd.
• Nov 2018
INTRODUCTION Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over...
Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth Summary The women’s health market represents a small but growing therapy area.There are currently 277 pipeline products in active development...
Ablation Equipments - Medical Devices Pipeline Assessment, 2019 Summary GlobalData’s Medical Devices sector report, “Ablation Equipments - Medical Devices Pipeline Assessment, 2019" provides an overview of Ablation Equipments currently in pipeline stage. The report provides comprehensive information...